Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 67

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 67
---
7,217 6,251 2,821 2025 Notes3,843 — 6,206 Weighted average number of RSUs2,139 1,033 417 Weighted average ESPP share options54 20 7      Total13,253 7,304 9,451 

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-36

Table of ContentsPACIRA BIOSCIENCES, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

NOTE 15—INCOME TAXES

(Loss) income before income taxes and the related tax expense (benefit) is as follows (in thousands):Year Ended December 31,202420232022(Loss) income before income taxes:   Domestic$(65,325)$66,257 $21,068    Foreign2,219 (4,556)(7,766)Total (loss) income before income taxes$(63,106)$61,701 $13,302 Current taxes:   Federal$9,295 $1,686 $—    State6,527 2,444 5,309    Foreign11 1 29       Total current taxes$15,833 $4,131 $5,338 Deferred taxes:   Federal$18,784 $16,790 $(2,781)   State1,837 (1,175)(5,164)      Total deferred taxes$20,621 $15,615 $(7,945)      Total income tax expense (benefit)$36,454 $19,746 $(2,607)A reconciliation of income tax expense (benefit) at the U.S. federal statutory rate to the provision for income taxes is as follows (dollars in thousands): Year Ended December 31, 202420232022AmountTax RateAmountTax RateAmountTax RateU.S. statutory rate applied to (loss) income before taxes$(13,252)21.00 %$12,957 21.00 %$2,793 21.00 %State taxes7,028 (11.14)%1,770 2.87 %508 3.82 %Foreign taxes(104)0.16 %(1